We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 34

The top 5 corruption risks for pharmaceutical and medical device companies

  • LeClairRyan
  • -
  • USA
  • -
  • September 19 2012

Pharmaceutical and medical device companies are fast becoming the enforcement punching bag, eclipsing the long-suffering status of the oil and gas energy

New Jersey Consumer Fraud Act

  • Day Pitney LLP
  • -
  • USA
  • -
  • September 13 2013

In a business-friendly decision, Perez v. Professionally Green, LLC, 214 N.J. ___ (2013), a unanimous New Jersey Supreme Court held yesterday that a

British man imprisoned in ‘Operation Singapore’ investigation

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • May 3 2011

The UK MHRA's 'Operation Singapore' investigation into the infiltration of counterfeit medicine into the UK's supply chain during five months in 2007 has concluded with a British man being sentenced to eight years imprisonment

U.S. Supreme Court: disclosing “statistically significant” incidents regarding a product’s potential adverse health effects is not enough

  • Kelley Drye & Warren LLP
  • -
  • USA
  • -
  • March 29 2011

The Supreme Court recently issued a unanimous decision in a securities fraud case, Matrixx Initiatives, Inc. v. Siracusano

Senate adopts food safety crime bill

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 22 2011

The U.S. Senate has approved a bill (S. 216) designed to “strengthen criminal penalties for companies that knowingly violate food safety standards and place tainted food products on the market,” according to the legislation’s sponsor, Senator Patrick Leahy (D-Vt

Matrixx Initiatives, Inc. v. Siracusano

  • Dorsey & Whitney LLP
  • -
  • USA
  • -
  • March 25 2011

Failure to disclose a statistically insignificant incidence of adverse side effects could lead to significant securities-fraud liability for publicly traded drugmakers, device manufacturers, and others under a recent Supreme Court decision

Boston Scientific prevails in securities fraud lawsuit

  • Winston & Strawn LLP
  • -
  • USA
  • -
  • August 22 2011

On August 15th, the First Circuit addressed what adverse events associated with medical devices an issuer must disclose, affirming the entry of summary judgment dismissing a Rule 10b-5 securities fraud lawsuit

FDA to increase enforcement actions against corporate officials

  • Faegre Baker Daniels
  • -
  • USA
  • -
  • March 5 2010

Corporate executives have rarely been personal targets of FDA enforcement actions

State prosecutors file consumer protection lawsuit against Toyota

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 18 2010

California state prosecutors have reportedly sued Toyota Motor Corp., alleging it engaged in fraud by concealing evidence of dangerous motor vehicle defects

GAO report calls for increase in FDA criminal prosecutions of company executives

  • Reed Smith LLP
  • -
  • USA
  • -
  • March 15 2010

The GAO recently issued a report entitled "Food and Drug Administration: Improved Monitoring and Development of Performance Measures Needed to Strengthen Oversight of Criminal and Misconduct Investigations," at the request of Senate Finance Committee Ranking Republican Charles Grassley